Use of angiotensin-converting-enzyme inhibitors in the management of renal disease.
The role of angiotensin-converting-enzyme inhibitors (ACEIs) in the treatment of progressive renal disease is described. Researchers have evaluated the use of ACEIs in patients with two types of progressive kidney disease: diabetic nephropathy and renal insufficiency associated with connective-tissue disease. When introduced early in the course of diabetic nephropathy, ACEIs appear to produce greater reductions in urinary protein concentrations than do other antihypertensive agents, even when systemic blood pressure does not decrease. They also slow the rate of decline of renal plasma flow and glomerular filtration rate. Results are less impressive when ACEIs are initiated at a later stage of disease. Captopril has been shown to be associated with a decline in serum creatinine level in patients with systemic scleroderma, and with reductions in blood pressure and increases in the glomerular filtration rate in patients with systemic lupus erythematosus. Because these patients were receiving other agents that might have influenced study outcome, specific conclusions about the efficacy of ACEIs in connective-tissue disease cannot yet be drawn. They may, however, be recommended as adjunctive agents in treatment of this condition. The relative safety of the ACEIs, combined with their ability to arrest or slow the progression of renal failure, makes them primary options in the management of selected renal diseases.
Asher
J P
JP
College of Pharmacy, University of South Carolina, Columbia.
Murray
K M
KM
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003240:Connective Tissue Diseases / Q000150:complications / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy
D000806:Angiotensin-Converting Enzyme Inhibitors; D005665:Furosemide